One of the most revolutionary developments of 2025 is the transition of bioprinting from Earth-based labs to the International Space Station (ISS). In February 2025, successful missions demonstrated that the absence of gravity allows for the printing of delicate tissue structures without the need for chemical scaffolds that can sometimes interfere with cell growth. In microgravity, the "Bio-ink" remains suspended, allowing for more complex vascularization—the creation of blood vessels—which is the primary hurdle for organ printing on Earth.

The Auxilium Microfabrication Platform has demonstrated the ability to print multiple implantable medical devices simultaneously in orbit with unmatched precision. Technical data regarding the viability of cells post-re-entry and the logistics of "Orbital Manufacturing" are explored in the Digital 3D Printing Market technology outlook. This space-based approach is proving to be a viable method for producing high-fidelity tendon and ligament implants that mimic the natural biomechanics of human tissue more accurately than any terrestrial method.